October 31, 2024

Corporate Travel Management (ASX:CTD) shared strong progress in a market update released today ahead of the company’s Annual General Meeting.  The report indicates gains in the company’s primary markets and effective cost management strategies. The Brisbane-based company operates across Australia, New Zealand, North America, Asia and Europe, providing tailored travel management solutions for corporate clients. […]

The Australian Bureau of Statistics (ABS) released a range of economic updates today, highlighting shifts across building approvals, export prices, and retail spending for September 2024. In building approvals, the seasonally adjusted total for dwellings rose by 4.4% to 14,842 units in September. This uptick follows a 3.9% fall in August. Private sector house approvals

In its quarterly report for the period ending 30 September 2024, BluGlass (ASX:BLG) shared details of a partnership with Uviquity, a US-based startup specialising in wide-bandgap semiconductors and integrated photonics. Under a multi-year Joint Development Agreement (JDA) announced on 31 October, BluGlass will receive an initial $1.2m for the first phase of a project to

Mineral Resources (ASX:MIN) has announced a pivotal $1.13bn deal with Hancock Prospecting, selling 100% of its exploration permits in the Perth Basin and forming joint ventures on remaining assets across the Perth and Carnarvon basins. This transaction, including an $804m upfront payment and up to $327m in resource-dependent bonuses, reflects MinRes’s strategy of leveraging high-value

Coles Group (ASX:COL) reported mixed results in its first quarter of FY2025, highlighting growth in some segments while grappling with tightened consumer spending in others. The company posted a 2.9% rise in total group revenue to reach $10.55bn for the 13 weeks ending 29 September 2024. Coles Supermarkets led the growth, with sales climbing 3.5%

JB Hi-Fi (ASX:JBH) has announced Q1 FY25 results, with a 4.9% total sales growth in JB Hi-Fi Australia, 19.6% growth in New Zealand, and 5.3% for The Good Guys, its consumer electronics and home appliances arm.  In FY24, JB Hi-Fi reached $9.6bn in sales, with a net profit after tax of $438.8m and a closing

Mesoblast (ASX:MSB; Nasdaq:MESO) has reported significant milestones in its Q1 FY2025 results, including an anticipated FDA decision on its lead product, Ryoncil (remestemcel-L), for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in children. Filed in July, the company expects an FDA verdict by 7 January 2025. Ryoncil would be the first FDA-approved treatment specifically